Communications and Marketing

Immunotherapies against cancer: German Cancer Research Center to broaden strategic alliance with Bayer HealthCare

No. 22 | 10/04/2013 | by nis

The German Cancer Research Center (DKFZ) and Bayer HealthCare (Bayer) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are promising to treat cancer by selectively reactivating the body's own immune system to attack tumor cells.


For the first time, scientists from the German Cancer Research Center and Bayer will work in a joint laboratory located at the National Center for Tumor Diseases (NCT) in Heidelberg to develop novel immunotherapies. The joint laboratory will accommodate up to twelve staff, and first projects are expected to start in the middle of this year. The partners will invest up to €3 million in total per year under the expanded alliance.

“The German Cancer Research Center's excellent expertise in basic research in oncology and Bayer's many years of experience in the development of new therapeutic options complement each other perfectly. Within the next five years, we aim to identify at least two new drug candidates in the field of cancer immunotherapy and to move them forward to the start of clinical trials,” says Prof. Dr. Otmar D. Wiestler, Chairman of the DKFZ's Management Board.

“We are looking forward to interlinking our collaboration with the German Cancer Research Center more closely to develop new treatment options in the field of immunotherapy for cancer patients,” said Professor Dr. Andreas Busch, Member of the Executive Committee of Bayer HealthCare and Head of Global Drug Discovery. “Bayer is committed to develop innovative therapies that can help people with serious diseases such as cancer to live longer and improve their quality of life.

The partners will build on established structures of their existing collaboration including joint review processes of individual projects and resource allocations. The rights to the research results are shared equally between the partners.

"The goal of one of our joint projects is to look for immunosuppressive molecules on the surface of tumor cells. In a next step we want to block them with antibodies and thereby activate the specific immune response against the tumor cells," explains Prof. Dr. Philipp Beckhove, Head of Translational Immunology at the DKFZ. "The new joint laboratory allows us to closely and continuously collaborate with the colleagues from Bayer and, thus, will support the faster translation of concepts from the lab into clinical trials."

The partners can already look back on four successful years of collaborative work. 22 projects have been initiated so far, and some of these have already passed important milestones. They moved on to the next phase of drug development, the compound screening for new potential drug candidates. Up to now, the two partners have invested more than €10 million in their ongoing joint research since 2008.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. At DKFZ, more than 1,300 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. DKFZ’s Cancer Information Service (KID) provides individual answers to all questions about cancer for patients, the general public, and health care professionals. Jointly with partners from Heidelberg University Hospital, DKFZ runs the National Center for Tumor Diseases (NCT) located in Heidelberg and Dresden, and, also in Heidelberg, the Hopp Children’s Cancer Center (KiTZ). In the German Cancer Consortium (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center at the NCT and DKTK sites is an important contribution to the endeavor of translating promising approaches from cancer research into the clinic in order to improve the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS